Abcellera Biologics Inc (ABCL NASDAQ) stock market data APIs
$4.6181
-0.14(-3%)
as of May 4, 2026
Try our APIs with
free plan!
Abcellera Biologics Inc Financial Data Overview
Price chart is built with
Anychart
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Prev. Close
4.6181
Open
4.4812
High
4.7234
Low
4.4372
52 wk Range
1.94-6.515
Market Cap
1 352 M
Shares Outstanding
305 M
Revenue
75 128 K
EPS
0
Beta
1.027
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abcellera Biologics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abcellera Biologics Inc data using free add-ons & libraries
Get Abcellera Biologics Inc Fundamental Data
Abcellera Biologics Inc Fundamental data includes:
- Net Revenue: 75 128 K
- EBITDA: -194 932 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.1275
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abcellera Biologics Inc News
New
AbCellera Biologics Among 3 Promising Penny Stocks
In the last week, the market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings forecast to grow by 16% annually. Though the term 'penny stock' might sound like a relic o...
JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best stocks under $5 with huge upside potential. On April 9, JonesResearch initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy ...
AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years
AbCellera Biologics Inc. (NASDAQ:ABCL) ranks among the stocks that could 10x over the next 5 years. On March 17, AbCellera Biologics Inc. (NASDAQ:ABCL) outlined its vision at the KeyBanc Capital Marke...
3 Penny Stocks With Market Caps Under $19B To Watch
The market remained flat over the last week, but it is up 16% over the past year, with earnings expected to grow by 15% annually in the coming years. For those interested in smaller or newer companies...
Get Abcellera Biologics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
